DETQ, a selective, allosteric, and orally active potentiator of the dopamine D1 receptor (Dopamine Receptor), enhances cAMP production in HEK293 cells expressing the human D1 receptor, achieving an EC50 of 5.8 nM and a K b of 26 nM. It demonstrates approximately 30-fold reduced potency at rat and mouse D1 receptors and shows no activity at the human D5 receptor [1].